Efficacy and Safety of Defibrotide to Treat Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Primary Chemotherapy: A Post Hoc Analysis of Final Data From an Expanded-Access Protocol

VOD/SOS, which may be unpredictable and potentially life-threatening, is typically considered a complication of hematopoietic stem cell transplantation (HSCT); VOD/SOS with multi-organ dysfunction (MOD) post-HSCT may be associated with>80% mortality. Defibrotide is approved to treat hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the US, and to treat severe hepatic VOD/SOS post-HSCT in the EU. However, VOD/SOS also can occur after chemotherapy without HSCT.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research